J.P. Morgan Maintains Buy Rating on Solid Biosciences
J.P. Morgan analyst Anupam Rama has maintained a "Buy" rating on Solid Biosciences (SLDB) and set a price target of $11.
Stocks · News reference
Solid Biosciences announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical programs for Duchenne muscular dystrophy and Friedreich's ataxia.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
J.P. Morgan analyst Anupam Rama has maintained a "Buy" rating on Solid Biosciences (SLDB) and set a price target of $11.
Circio Holding ASA has entered into a collaboration with Solid Biosciences to advance the development of a gene therapy candidate for genetic heart disease.
William Blair analyst Alethia Young initiated coverage on Solid Biosciences (SLDB) with a Buy rating and a price target of $11.
Solid Biosciences announced that its President and CEO, Bo Cumbo, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.